Patents by Inventor Theresa A. Branchek
Theresa A. Branchek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030008823Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT1F receptor, an isolated protein which is a human 5-HT1F receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT1F receptors. mammalian cells comprising such vectors, antibodies directed to the human 5-HT1F receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT1F receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT1F receptor, pharmaceutical compounds related to human 5-HT1F receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT1F receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT1F receptor.Type: ApplicationFiled: June 10, 2002Publication date: January 9, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 6475746Abstract: This invention provides isolated nucleic acid molecules encoding human 5-HT1D receptors, isolated proteins which are human 5-HT1D receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT1D receptors, mammalian cells comprising such vectors, antibodies directed to human 5-HT1D receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT1D receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT1D receptor, pharmaceutical compounds related to human 5-HT1D receptors, and nonhuman transgenic animals which express DNA which encodes a normal or a mutant human 5-HT1D receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT1D receptor.Type: GrantFiled: August 9, 1999Date of Patent: November 5, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Publication number: 20020115149Abstract: This invention provides isolated nucleic acid molecules encoding human 5-HT1D receptors, isolated proteins which are human 5-HT1D receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT1D receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT1D receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT1D receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT1D receptor, pharmaceutical compounds related to human 5-HT1D receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT1D receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT1D receptor.Type: ApplicationFiled: October 29, 2001Publication date: August 22, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 6432655Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor and an isolated nucleic acid molecule encoding a human 5-HT4B receptor, an isolated protein which is a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4B receptor, pharmaceutical compounds related to the human 5-HT4B receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT4B receptor.Type: GrantFiled: June 14, 1999Date of Patent: August 13, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Publication number: 20020103123Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor.Type: ApplicationFiled: September 24, 2001Publication date: August 1, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
-
Publication number: 20020098548Abstract: The present invention provides an isolated nucleic acid molecule encoding an 5-HT2 receptor, and an isolated protein which is a human 5-HT2 receptor.Type: ApplicationFiled: August 14, 2001Publication date: July 25, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
-
Patent number: 6420532Abstract: This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.Type: GrantFiled: September 29, 1999Date of Patent: July 16, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe Gerald, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
-
Publication number: 20020081661Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4 receptor and an isolated nucleic acid molecule encoding a human 5-HT4 receptor, an isolated protein which is a mammalian 5-HT4 receptor, an isolated protein which is a human 5-HT4 receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4 receptor, vectors comprising and isolated nucleic acid molecule encoding a human 5-HT4 receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4 receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4 receptor, pharmaceutical compounds related to the human 5-HT4 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT4 receptor.Type: ApplicationFiled: November 19, 2001Publication date: June 27, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Christophe P.G Gerald, Paul R. Hartig, Theresa A. Branchek, Richard L. Weinshank
-
Patent number: 6406859Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT1F receptor, an isolated protein which is a human 5-HT1F receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT1F receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT1F receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT1F receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT1F receptor, pharmaceutical compounds related to human 5-HT1F receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT1F receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT1F receptor.Type: GrantFiled: February 5, 1999Date of Patent: June 18, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 6383762Abstract: The present invention provides a method of obtaining a composition which comprises determining whether a chemical compound binds to a human 5-HT2 receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to the receptor, admixing the compound with a carrier. The present invention further provides a method of obtaining a composition which comprises determining whether a chemical compound binds to and activates or binds to and inhibits activation of a human 5-HT2 receptor expressed on the surface of a mammalian cell, wherein the human 5-HT2 receptor is expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to and activates or binds to and inhibits activation of the receptor, admixing the compound with a carrier.Type: GrantFiled: September 2, 1998Date of Patent: May 7, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
-
Patent number: 6376243Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor and an isolated nucleic acid molecule encoding a human 5-HT4B receptor, an isolated protein which is a mammalian 5-HT4B receptor, an isolated protein which is a human 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4B receptor, pharmaceutical compounds related to the human 5-HT4B receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT4B receptor.Type: GrantFiled: November 29, 1999Date of Patent: April 23, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6368812Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: April 9, 1998Date of Patent: April 9, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Publication number: 20020032219Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.Type: ApplicationFiled: November 22, 1999Publication date: March 14, 2002Inventors: CHARLES GLUCHOWSKI, CARLOS C. FORRAY, GEORGE CHIU, THERESA A. BRANCHEK, JOHN M. WETZEL, PAUL R. HARTIG
-
Patent number: 6331401Abstract: The present invention provides a process for identifying a chemical compound which specifically binds to a rat or human 5-HT4 receptor. The invention also provides a process involving competitive binding for identifying a chemical compound which specifically binds to a rat or human 5-HT4 receptor. The invention provides for a process for determining whether a chemical compound specifically binds to and activates a rat or human 5-HT4 receptor. The invention additionally provides for a process for determining whether a chemical compound specifically binds to and inhibits activation of a rat or human 5-HT4 receptor.Type: GrantFiled: April 3, 1998Date of Patent: December 18, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe Gerald, Paul R. Hartig, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6316203Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.Type: GrantFiled: November 25, 1998Date of Patent: November 13, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
-
Patent number: 6300087Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor and an isolated nucleic acid molecule encoding a human 5-HT4B receptor, an isolated protein which is mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT4B receptor, pharmaceutical compounds related to the human 5-HT4B receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT4B receptor.Type: GrantFiled: November 29, 1999Date of Patent: October 9, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
-
Patent number: 6287788Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: November 25, 1998Date of Patent: September 11, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Patent number: 6127131Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds rType: GrantFiled: May 26, 1998Date of Patent: October 3, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, Laurence A. Borden, Theresa Branchek, Paul R. Hartig, Richard L. Weinshank
-
Patent number: 6096507Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptor, an isolated protein which is a human 5-HT.sub.1E receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1E receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1E receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1E at receptor, pharmaceutical compounds related to human 5-HT.sub.1E receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1E receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1E receptor.Type: GrantFiled: February 4, 1998Date of Patent: August 1, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
-
Patent number: 6083749Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4B receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4B receptor, an isolated protein which is a mammalian 5-HT.sub.4B receptor, an isolated protein which is a human 5-HT.sub.4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4B receptor, pharmaceutical compounds related to the human 5-HT.sub.4B receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4B receptor.Type: GrantFiled: July 27, 1994Date of Patent: July 4, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Theresa Branchek, Richard L Weinshank